Lead Product(s): Ciprofloxacin
Therapeutic Area: Pulmonary/Respiratory Diseases
Highest Development Status: Phase III Product Type: Small molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 02, 2020
Under the terms of the agreement, Savara has obtained the worldwide rights to develop and commercialize Apulmiq.